Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects*

Maria Isabel Ramos Saraiva1,3, Larissa Karine Leite Portocarrero1, Marcella Amaral Horta Barbosa Vieira1, Bethania Cabral Cavalli Swiczar1, Andrezza Telles Westin2

DOI: http://dx.doi.org/10.1590/abd1806-4841.20186982

Abstract: Background: Actinic keratoses are benign intraepithelial skin neoplasms that develop in photoexposed areas and can progress to invasive carcinoma. They are seen frequently in dermatological practice, occurring in 5.1% of consultations. Ingenol mebutate (IM) was recently approved in Brazil as a topical therapy for field cancerization in actinic keratoses.

Objective: To evaluate the clearance rate and adverse events in the treatment of actinic keratoses with ingenol mebutate.

Methods: A longitudinal, prospective, non-randomized, interventional, open, single-center study was conducted. Patients with actinic keratoses applied ingenol mebutate on a 25cm² area of the face and/or scalp for three consecutive days (0.015%) or on the forearm for two days (0.05%).

Results: 27 patients completed the protocol, of whom 13 on the face and/or scalp and 14 on the forearm. Complete clearance occurred in 53.8% in the first group and 42.8% in the second. Partial response was observed in 15.4% and 35.7%, respectively. The most common side effects were erythema, edema, desquamation, pruritus, and local erosion.

Study limitations: The study had a small sample and was not randomized, double-blind, placebo-controlled, or vehicle-controlled.

Conclusion: Ingenol mebutate is well-tolerated for the treatment of actinic keratosis, with good patient adherence thanks to the short treatment period.

Keywords: Keratosis, actinic; Skin neoplasms; Therapeutics; Treatment outcome

INTRODUCTION

Skin alterations in response to sun exposure have increased dramatically in the last 50 years due to population aging and increased exposure to ultraviolet (UV) radiation.1 Solar keratosis, senile keratosis, or actinic keratosis (AK) are benign intraepithelial neoplasms, formed by atypical keratinocyte proliferation, common in photo-exposed areas. They comprise a significant share of dermatology practice and are considered the fourth most frequent diagnosis, occurring in 5.1% of patient consultations in Brazilian statistics for 2006.2

AK mainly affects individuals with low phototypes and, increasingly, immunosuppressed individuals.2 Secondary factors for the development of AK are advanced age, male gender, birthplace with higher UV index, Caucasoid ethnic group, previous history of cutaneous neoplasms, work history with sun exposure, and low socioeconomic status.2,3

Actinic keratosis results from the adverse effects of UV radiation on keratinocyte DNA, reducing the skin’s immunity and thus allowing the lesion development. The mutations p16 (INK4a; 9p21), p14 (ARF), p15 (INK4b), and p53 are closely associated with increased risk of progression to squamous cell carcinoma (SCC).4 Clinically, the lesions grow slowly and are characterized by erythematous papules, pigmented or not, that can be covered with yellowish or brownish scales, with little or no infiltration, measur-
ing less than 1 cm in diameter. The adjacent skin can show evidence of chronic sun damage with telangiectasias, elastosis, wrinkles, poikiloderma, and dyschromia. AKs can regress spontaneously, remain stable, or transform into invasive SCC. Currently, AKs are considered intraepithelial neoplasms of keratinocytes, with a cumulative risk (5–20%) of evolving to invasive neoplasm within 10–25 years, with the number of lesions maximizing this occurrence. An estimated 27–82% of cutaneous SCCs evolve from AK, and 82–97% of SCCs present contiguous AKs. Various methods can be used to treat atypical keratinocytes in order to reduce the risk of invasive SCC.

The concept of “field carcinization” suggests that apparently normal skin adjacent to the AK area already presents genetic alterations associated with carcinogenesis. Patients with AK typically have multiple lesions, reflecting local sun damage. Based on this concept, the management is divided into therapies targeted to the lesion and the field.

The therapies targeted to the lesion include cryotherapy, trichloroacetic acid (TAA), curettage with electrocoagulation, shaving, peeling, and laser), and application of topical medications such as 5-fluorouracil, diclofenac, and sodium diclofenac with 5-aminolevulinic acid, and more recently, ingenol mebutate (IM). IM is a macrocyclic diterpene ester, obtained from the natural extract of the plant Euphorbia peplus. IM is the drug most recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-hyperkeratotic and non-hypertrophic AKs in adults.

This new drug presents two mechanisms of action: rapid induction of cell death in the treated area a few hours after application and an inflammatory response in a few days after application, capable of eliminating the residual cells. The keratinocyte’s death appears to be related to necrosis through mitochondrial edema and chemoablation with rupture of the plasma membrane. The inflammatory response is caused by both the cell necrosis and activation of protein kinase C, capable of stimulating the release of proinflammatory cytokines, expression of endothelial adhesion molecules, and production of tumor-specific antibodies and leading to cytotoxicity mediated by antibody-dependent neutrophils.

The drug in gel form is available in two presentations, one at a concentration of 150 μg/g for application on the target area of the face or scalp once a day for three consecutive days, and the other at 500 μg/g for use on the trunk or extremities for two consecutive days. The tube’s content should be applied on an affected area measuring a maximum of 25 cm².

The most common adverse reactions include erythema, desquamation, and formation of crusts. These reactions are most intense from the third to eighth day from initiation of treatment, with spontaneous improvement within two to four weeks. Edema, formation of pustules, erosion, and ulceration can also occur. There are no reports of scarring. Anderson et al. demonstrated statistically significant improvement in patients treated with IM when compared to controls (placebo) 57 days after initiating treatment.

There is growing interest in combined therapies for AKs, especially with the advent of new treatment options. However, the final choice of treatment should assess not only efficacy, but also the adverse reactions, aesthetic results, access, cost, and patient’s choice.

This study aims to assess the clearance of lesions and the adverse events in the treatment of actinic keratoses with ingenol mebutate used on the face/scalp and limbs.

**METHOD**

This was a longitudinal, prospective, non-randomized, non-placebo-controlled, interventional, open, single-center study approved by the Institutional Review Board indicated by the Brazilian Platform under case review number 42933914.9.0000.5463. The study only enrolled patients that agreed to participate by signing the free and informed consent form and authorizing use of the photographs of the treated areas.

Complete treatment was provided free of cost to patients by the product’s manufacturer. Conflict of interest: provision of the medication by the manufacturer. Eligibility criteria included age over 18 years, willingness to collaborate, and presence of 4 to 8 typical, non-hypertrophic, contiguous actinic keratosis lesions on an area of up to 25 cm² on the face, scalp, or upper limbs, not previously or currently treated. Subjects neither had a known history of allergy or sensitivity to any component of the formula, nor were using immunosuppressants.

Patients were divided into 2 groups. The first consisted of patients with lesions on the face or scalp and the second, patients with lesions on the limbs. Patients in the first group received IM 150 mcg/g for three consecutive days, while the second group received IM 500 mcg/g for two consecutive days. The product was applied by physicians on D1, and the remaining doses were applied by the patients themselves at home.

On each treatment day, the tube’s content was applied on an area measuring 25 cm², spread homogeneously, and left to dry for 15 minutes. Patients were instructed to wash their hands immediately after the application, not to touch the treated area for six hours or expose the area to sun, to store the tubes under refrigeration (2 to 8°C) until their use, and to discard them after opening and use.

Patients were assessed 7 days (D7) after initiating application of the medication, and photographic records were performed, along with analysis of adverse events (pain, local infection, edema, ulcer, pruritus, erythema, desquamation, and paresthesia).

Patients also returned at 57 days (D57) following initiation of treatment for the final evaluation and a new photographic record. At this final follow-up, the treated area was analyzed for clinical clearance of lesions based on counting the residual AKs. We assessed the mean percentage reduction in the lesions, with treatment response classified as follows: complete clearance (100% improvement in the AKs), i.e., no residual AK; partial clearance (>75% improvement of AKs), or a decrease of more than 75% in the number of AKs; without clearance (improvement <75%), or resolution of less than 75% in the initial number of AKs. Persistent adverse events and...
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects

Figure 1: D1, D7, and D57 in right malar region treated for three days with IM 0.015%. On D1 there were four AK lesions, while on D57 there were no lesions. On D7, intense erythema, edema, desquamation, and crusting.

Figure 2: D1, D7, and D57 in left temporal region treated for three days with IM 0.015%. On D1 there were four AK lesions, while on D57 there were no lesions. On D7, mild erythema, desquamation, and crusting.

RESULTS

Thirty-one patients were initially selected to participate in the study, of whom 15 patients were assigned to application on the face or scalp and 16 for application on the forearm. Three patients were eventually excluded from the study for not appearing on all the scheduled days, and one for not using the medication correctly.

Group 1: Face and scalp

This group consisted of 13 patients from 65 to 86 years of age (mean 74.5 years), including 53.8% men and 46.2% women. According to the Fitzpatrick classification, 38.5% were phototype I; 53.8%, phototype II; and 7.7% phototype III. The number of AK lesions on the target area ranged from 4 to 7, with a mean of 5.1 lesions. Complete clearance of the lesions occurred in 53.8% of the treated patients; 15.4% showed partial clearance; 30.8% had improvement less than or equal to 50%. Thus, when effective improvement was defined as clearance of more than 75% of the lesions, 69.2% of the treated patients showed a good response (Figure 1). There was a mean reduction of 75.8% when compared to the baseline values in the number of AKs in the treated patients. The most common adverse effects observed at D7 after application of IM were erythema, edema, desquamation, pruritis, and erosion on the application site (Figure 2). The majority of the adverse effects were transient, with spontaneous resolution observed at D57, with persistent erythema and desquamation in only 15% of the patients, as shown in table 1.

Group 2: Forearm

The 14 patients allocated to this group ranged in age from 61 to 88 years, with a mean of 73.2 years. Of these, 64.3% were men and 35.7% women. As to Fitzpatrick classification, 28.6% were phototype I; 50% phototype II; and 21.4% phototype III. The number of AK lesions in the target area varied from four to eight, with a mean of 6.5 lesions. There was complete clearance of the lesions in 42.8% of the patients in this group; 35.7% showed partial clearance; 21.5% showed improvement between 25 and 50%. Thus, 78.5% of the patients showed good response to treatment, with clearance of more than 75% of the lesions (Figures 3 and 4). There was a mean reduction of 87.9% compared to baseline in the number of AKs in the treated patients. The most common adverse effects observed at D7 after application of ingenol mebutate were erythema, edema, desquamation, and pruritis at the application site, the majority of which were transient, with spontaneous resolution observed at D57, with persistent erythema in 28.6% of the patients and edema in 7.1%, as shown in table 2.
DISCUSSION

Topical treatment of field cancerization for AK applied by the patient should be effective, safe, and user-friendly in order to allow completing the treatment.8

In this study, treatment with IM gel 0.015% or 0.05% applied on the face/scalp or forearm, respectively, was found to be well-tolerated, and the adverse effects were considered mild and mostly transient. Anderson et al., reported similar findings, with partial clearance in patients treated with IM in non-facial areas varying from 56 to 75.4% compared to 21.7% with the vehicle. The complete response rate was also significantly higher in patients treated with IM, i.e., from 40 to 54.4%, compared to 1.7% improvement in the group treated with the vehicle.9 Lebwohl et al. demonstrated the superiority of IM in lesions on the trunk and extremities, with 49.1% partial improvement compared to 6.9% in the placebo group. Complete response was seen in 34.1% in the IM group, compared to 4.7% in the placebo group. Median reduction in the number of lesions was 75% in the group treated with IM, compared to 0% in the placebo group. Lesions on the face and scalp showed complete improvement in 42.2% at D57 in patients treated with IM, compared to 3.7% in the placebo group. The treated group showed partial improvement in 63.9% of the patients, compared to 7.4% in the placebo group. Median reduction in the number of lesions was 83% in the treated group, compared to zero response in the placebo group.8

There are numerous topical options currently available for the treatment of field cancerization in AK, with various dosages, treatment times, efficacy, and adverse event profiles. Stockfleter et al., in a systematic review on the use of topical treatments for AK, performed a qualitative comparison showing complete clinical response with 5-fluorouracil (55.5%), followed by IM (42.2%), and imiquimod 3.75% (25-35.6%).10 Studies that used 5-fluorouracil treated hyperkeratotic lesions, which are more aggressive, with greater potential for malignant transformation, while studies with IM and imiquimod did not.10

Gupta et al. reviewed various therapeutic interventions for AK, aimed at treatment of field cancerization. The different therapies that were analyzed (diclofenac 3%, 5-fluorouracil 0.5%, imiquimod 5%, and IM at 0.015% and 0.005%) showed similar efficacy but were associated with different cosmetic outcomes and adverse effects, with the following dropout rates: 144 of 1,000 participants in the group treated with diclofenac sodium in hyaluronic acid 2.5%; 40 of 1,000 participants using only hyaluronic acid 2.5%; and 56 of 1,000 using imiquimod 5%, compared to 21 of 1,000 patients that received placebo. The study did not report the dropout rate for patients that used IM. The authors suggested that more studies were needed to compare the various treatment modalities.11 Sotiriou et al. used photodynamic therapy with aminolevulinic acid for treatment of field cancerization and observed a 65.32% response rate in six months of follow-up for two treatment sessions.12 Samorano et al. found that local reactions with IM were less lasting when compared to 5-fluorouracil, but that both were safe and well-tolerated.13

In our study, all the patients had adverse effects at D7, which were expected for the treatment. There was good tolerability, with 33.3% presenting prolonged adverse effects (erythema 25.9%, desquamation 7.4%, scaling 7.4%, pruritis 7.4%, periorbital edema 3.7%, and hypochromia 3.7%), none of which were considered serious. The persistence of these effects had already been observed in a previous study, showing alterations in pigmentation in all the study groups, besides minimal scarring.9 Patients treated with IM that presented higher grade inflammation resulting from the medication ap-

| Table 1: Adverse effects observed on the face at days 7 and 57 |
|---------------------------------|-------|
| **Adverse effect on face**      | **D7** | **D57** |
| Infection                       | 15.4% |       |
| Headache                        | 15.4% |       |
| Periorbital edema               | 23.1% | 7.7%  |
| Erosion                         | 46.2% |       |
| Vesicles                        | 38.5% |       |
| Local edema                     | 53.8% |       |
| Desquamation                    | 61.5% | 7.7%  |
| Scaling                         | 53.8% | 15.4% |
| Erythema                        | 69.2% | 15.4% |
| Pain                            | 38.5% |       |
| Pruritus                        | 84.6% | 7.7%  |
| Paresthesia                     | 7.7%  |       |
| Ulcer                           | 7.7%  |       |
| Hypochromia                     | 7.7%  |       |

FIGURE 3: D1, D7, and D57 on forearm treated for two days with IM 0.05%. On D1 there were six AK lesions, while on D57 there was one lesion. On D7, intense erythema, desquamation, and crusting.
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects

Figure 4: D1, D7, and D57 on forearm treated for two days with IM 0.05%. On D1 there were six AK lesions, while on D57 there was one lesion. On D7, moderate erythema, desquamation, crusting have evolved with more significant clinical improvement of the treated area, based on aesthetic and therapeutic improvement, but more studies are necessary.

As for dosage, we observed high treatment adherence, since 90% of patients completed treatment, appearing for follow-up at both D7 and D57, which had been reported previously by Matin and Swanson. The dosing schedule can be advantageous when compared to other drugs, since it requires shorter treatment times, and the adverse effects only began after completing the prescribed treatment regimen. It is thus recommended to apply the product in the physician’s office or clinic in order to avoid inadequate use of the medication. The main advantage of treatment with ingenol mebutate is that similar degrees of efficacy can be achieved with only two or three days of treatment.

The study had the following limitations: low number of patients, lack of blinding, lack of placebo control, no direct comparison with other medications, and lack of follow-up at one year. Neither did the study assess the reasons for patients’ failure to appear on the scheduled days, and no biopsies were performed to prove the diagnosis prior to treatment, nor after treatment to prove clinical improvement. Since the treatment was performed on exposed areas like the face, we opted to perform diagnostic and follow-up exclusively according to clinical and dermoscopic criteria. Since the study was not a randomized clinical trial, it did not assess efficacy and safety, but it does corroborate some findings already published in the world literature.

CONCLUSION
Patients that used ingenol mebutate showed good clearance of the lesions and foreseeable adverse events. The short treatment period appears to have facilitated patients’ adherence. We thus conclude that IM can be an option in the therapeutic armamentarium for AK.

ACKNOWLEDGEMENT
The authors wish to thank Dr. José Alexandre de Souza Sittart for his encouragement and support for conducting this study.

Table 2: Adverse effects observed on the forearm at days 7 and 57

| Adverse event on forearm D7 D57 | D7 D57 |
|--------------------------------|--------|
| Infection                      | 7.1%   |
| Headache                       | 7.1%   |
| Erosion                        | 14.3%  |
| Vesicles                       | 42.8%  |
| Local edema                    | 28.6%  |
| Desquamation                   | 85.7%  7.1% |
| Scaling                        | 28.6%  |
| Erythema                       | 85.7%  28.6% |
| Pain                           | 35.7%  |
| Pruritis                       | 85.7%  |
| Paresthesia                    | -      |
| Ulcer                          | -      |
| Hypochromia                    | -      |
REFERENCES

1. Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68:520-7.
2. Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol. 2012;87:425-34.
3. de Berker D, McGregor JM, Hughes BR. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-30.
4. Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb). 2014;4:11-31.
5. Costa C, Scaldenzi M, Ayala F, Fabbricini G, Monfrecola G. How to treat actinic keratosis? An update. J Dermatol Case Rep. 2015;9:29-35.
6. de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-30.
7. Micali G, Nasca MR, De Pasquale R. Erythroplasia of Queyrat treated with imiquimod 5% cream. J Am Acad Dermatol. 2006;55:901-3.
8. Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Slough DB, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934-43.
9. Stockfleth E, Sibbring GC, Alarcon I. New Topical Treatment Options for Actinic Keratosis: A Systematic Review. Acta Derm Venereol. 2016;96:17-22.
10. Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415.
11. Sotiriou E, Apalla Z, Mallamani F, Zaparas N, Panagiotidou D, Ioannides D. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol. 2009;23:1061-5.
12. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68:S39-48.

AUTHORS CONTRIBUTION

Maria Isabel Ramos Saraiva
Statistical analysis; Approval of the final version of the manuscript; Elaboration and writing of the manuscript; Obtaining, analyzing and interpreting the data; Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied; Critical review of the literature; Critical review of the manuscript

Larissa Karine Leite Portocarrero
Statistical analysis; Approval of the final version of the manuscript; Elaboration and writing of the manuscript; Obtaining, analyzing and interpreting the data; Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied; Critical review of the literature; Critical review of the manuscript

Marcella Amaral Horta Barbosa Vieira
Statistical analysis; Approval of the final version of the manuscript; Elaboration and writing of the manuscript; Obtaining, analyzing and interpreting the data; Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied; Critical review of the literature; Critical review of the manuscript

Bethania Cabral Cavalli Swiczar
Approval of the final version of the manuscript; Conception and planning of the study; Effective participation in research orientation; Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied; Critical review of the manuscript

Andrezza Telles Westin
Approval of the final version of the manuscript; Conception and planning of the study; Obtaining, analyzing and interpreting the data; Effective participation in research orientation; Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied; Critical review of the manuscript

How to cite this article: Saraiva MIR, Portocarrero LKL, Vieira MAHB, Swiczar BCC, Westin AT. Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects. An Bras Dermatol. 2018;93(4):529-34.